PMID- 21988324
OWN - NLM
STAT- MEDLINE
DCOM- 20121002
LR  - 20211020
IS  - 1557-8534 (Electronic)
IS  - 1547-3287 (Print)
IS  - 1547-3287 (Linking)
VI  - 21
IP  - 9
DP  - 2012 Jun 10
TI  - Oral mucosal progenitor cells are potently immunosuppressive in a 
      dose-independent manner.
PG  - 1478-87
LID - 10.1089/scd.2011.0434 [doi]
AB  - Oral mucosal lamina propria progenitor cells (OMLP-PCs) are a novel, clonally 
      derived PC population of neural crest origin with the potential to differentiate 
      down both mesenchymal and neuronal cell lineages. In this study we aimed to 
      determine the immunological properties of OMLP-PCs and to establish whether they 
      would be suitable candidates for allogeneic tissue engineering and in the 
      treatment of immune-related diseases. OMLP-PCs demonstrated no inherent 
      immunogenicity with insignificant expression of costimulatory molecules (CD40, 
      CD80, CD86, CD154, and CD178) or human leukocyte antigen (HLA) class II. OMLP-PCs 
      required 7 days of stimulation with interferon-gamma (IFN-gamma) to induce cell surface 
      expression of HLA II. Mixed lymphocyte cultures and mitogen stimulation 
      demonstrated the potent immunosuppressive capability of OMLP-PCs in a 
      contact-independent manner. Complete inhibition of lymphocyte proliferation was 
      seen at doses as low as 0.001% OMLP-PCs to responder lymphocytes, while annexin V 
      staining confirmed that this immunosuppressive effect was not due to the 
      induction of lymphocyte apoptosis. These data demonstrate, for the first time, 
      that OMLP-PC immunomodulation, unlike that for mesenchymal stem cells, occurs via 
      a dose- and HLA II-independent mechanism by the release of immunosuppressive 
      soluble factors and suggests these cells may have wide ranging potential in 
      future immune-related therapies.
FAU - Davies, Lindsay C
AU  - Davies LC
AD  - Wound Biology Group, Cardiff Institute of Tissue Engineering and Repair, Tissue 
      Engineering and Reparative Dentistry, School of Dentistry, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Lonnies, Helena
AU  - Lonnies H
FAU - Locke, Matthew
AU  - Locke M
FAU - Sundberg, Berit
AU  - Sundberg B
FAU - Rosendahl, Kerstin
AU  - Rosendahl K
FAU - Gotherstrom, Cecilia
AU  - Gotherstrom C
FAU - Le Blanc, Katarina
AU  - Le Blanc K
FAU - Stephens, Phil
AU  - Stephens P
LA  - eng
GR  - G0901562/Medical Research Council/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120207
PL  - United States
TA  - Stem Cells Dev
JT  - Stem cells and development
JID - 101197107
RN  - 0 (Antigens, CD)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antigens, CD/immunology
MH  - Apoptosis/immunology
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Dose-Response Relationship, Immunologic
MH  - Female
MH  - Humans
MH  - Immune System Diseases/immunology/therapy
MH  - *Immune Tolerance
MH  - Interferon-gamma/immunology
MH  - Lymphocytes/*cytology/*immunology
MH  - Male
MH  - Mouth Mucosa/*cytology/*immunology
MH  - Stem Cells/*cytology/*immunology
MH  - Tissue Engineering
PMC - PMC3359631
EDAT- 2011/10/13 06:00
MHDA- 2012/10/04 06:00
PMCR- 2011/10/11
CRDT- 2011/10/13 06:00
PHST- 2011/10/13 06:00 [entrez]
PHST- 2011/10/13 06:00 [pubmed]
PHST- 2012/10/04 06:00 [medline]
PHST- 2011/10/11 00:00 [pmc-release]
AID - 10.1089/scd.2011.0434 [pii]
AID - 10.1089/scd.2011.0434 [doi]
PST - ppublish
SO  - Stem Cells Dev. 2012 Jun 10;21(9):1478-87. doi: 10.1089/scd.2011.0434. Epub 2012 
      Feb 7.